Everything below concerns Laboratory compound. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
mRNA-based disease diagnosis technologies are diagnostic procedures using messenger RNAs. as molecular diagnostic tools to discover the relationships between patient's DNAs and their specific biological features. The mRNA-based disease diagnosis technologies have been applied to medical field widely in recent years, especially on early diagnosis of tumors (such as renal cell carcinoma, hepatocellular carcinoma, breast cancer and prostate cancer). The technology can be applied to various types of samples depending on how easily the samples are accessible and whether the samples reliably contain the mRNA that related to specific diseases. For example, in hepatocellular carcinoma, the tumor tissues excised during the operation are a good resource for mRNA-based test to analysis. Among those most commonly used samples, blood sample is one of the most easily accessible via minimally invasive method. degenerative diseases . Blood has been used in early diagnosis of some cancers, such as non-small lung cancer and neuroendocrine tumors.
Flagella in eukaryotes are supported by microtubules in a characteristic arrangement, with nine fused pairs surrounding two central singlets. These arise from a basal body. In some flagellates, flagella direct food into a cytostome or mouth, where food is ingested. Flagella role in classifying eukaryotes. Among protoctists and microscopic animals, a flagellate is an organism with one or more flagella. Some cells in other animals may be flagellate, for instance the spermatozoa of most animal phyla. Flowering plants do not produce flagellate cells, but ferns, mosses, green algae, and some gymnosperms and closely related plants do so. Likewise, most fungi do not produce cells with flagellae, but the primitive fungal chytrids do. Many protists take the form of single-celled flagellates.
2. Int J Pharm Compd. 2026 Jul-Aug;30(4):329-336. Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards. Willis J(1), Vu N(2)(3). Author information: (1)University of Oklahoma College of Pharmacy. (2)ARL Bio Pharma, Oklahoma City, Oklahoma. Nvu@arlok.com. (3)University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma. Compounded peptides have quickly moved from a niche topic to a growing area of interest among patients and prescribers. These products are promoted for a wide range of uses, including tissue repair, inflammation, metabolic health, and healthy aging. This article examines the proposed uses of these peptides, the concerns raised during the review, and the practical implications for compounders. Copyright© by International Journal of Pharmaceutical Compounding, Inc.
Sources: en.wikipedia.org
Sulfonylureas – glimepiride, glipizide, glyburide Biguanides – metformin Thiazolidinediones (Tzd) – pioglitazone, Actos generic Alpha-glucosidase inhibitors – Acarbose Meglitinides – nateglinide Combination of sulfonylureas plus metformin – known by generic names of the two drugs No generics are available for dipeptidyl peptidase-4 inhibitors (Onglyza), the glifozins, the incretins and various combinations. Sitagliptin patent expired in July 2022, leading to launch of generic sitagliptin brands . This lowered the cost of therapy for type 2 diabetes using sitagliptin .
=== Insects === Order Blattodea Blattella germanica, German cockroach (2018) Periplaneta americana, American cockroach (2018) Zootermopsis nevadensis, a dampwood termite (2014 Cryptotermes secundus, a drywood termite(2018) Macrotermes natalensis, a higher termite (2014 Order Coleoptera Dendroctonus ponderosae Hopkins, beetle (mountain pine beetle) (2013) Aquatica lateralis, Japanese aquatic firefly "Heike-botaru" (firefly) (2018) Photinus pyralis, Big Dipper firefly (2018) Protaetia brevitarsis, White-spotted flower chafer (2019) Tribolium castaneum Strain:GA-2, beetle (red flour beetle) (2008) Allomyrina dichotoma, Japanese rhinoceros beetle (2022) Pachyrhynchus sulphureomaculatus, Easter Egg Weevil (2021) Order Collembola Family Isotomidae Desoria tigrina, (2021) Family Sminthurididae Sminthurides aquaticus, (2021) Order Diptera Family Calliphoridae Aldrichina grahami, Forensic blowfly (2020) Family Chironomidae Dasypogon diadema, Hunting Robber fly (2019) Parochlus steinend, Antarctic winged midge (2017) Proctacanthus coquilletti, Assassin fly (2017) Family Culicidae (mosquitoes) Aedes aegypti Strain:LVPib12, mosquito (vector of dengue fever, etc.) (2007) Aedes albopictus (2015) Anopheles darlingi Anopheles gambiae Strain: PEST, mosquito (vector of malaria) (2002) Anopheles gambiae Strain: M, mosquito (vector of malaria) (2010) Anopheles gambiae Strain: S, mosquito (vector of malaria) (2010) Anopheles sinensis, mosquito (vector of vivax malaria, lymphatic filariasis and Setaria infections), (2014) Anopheles stephensii Anopheles arabiensis (2015) Anopheles quadriannulatus (2015) Anopheles merus (2015) Anopheles melas (2015) Anopheles christyi (2015) Anopheles epiroticus (2015) Anopheles maculatus (2015) Anopheles culicifacies (2015) Anopheles minimus (2015) Anopheles funestus (2015, 2019) Anopheles dirus (2015) Anopheles farauti (2015) Anopheles atroparvus (2015) Anopheles sinensis (2015) Anopheles albimanus (2015) Culex quinquefasciatus, mosquito (vector of West Nile virus, filariasis etc.) (2010) Family Drosophilidae (fruit flies) Drosophila albomicans, fruit fly (2012) Drosophila ananassae, fruit fly (2007) Drosophila biarmipes, fruit fly (2011) Drosophila bipectinata, fruit fly (2011) Drosophila erecta, fruit fly (2007) Drosophila elegans, fruit fly (2011) Drosophila eugracilis, fruit fly (2011) Drosophila ficusphila, fruit fly (2011) Drosophila grimshawi, fruit fly (2007) Drosophila kikkawai, fruit fly (2011) Drosophila melanogaster, fruit fly (model organism) (2000) Drosophila mojavensis, fruit fly (2007) Drosophila neotestacea, fruit fly (transcriptome 2014) Drosophila persimilis, fruit fly (2007) Drosophila pseudoobscura, fruit fly (2005) Drosophila rhopaloa, fruit fly (2011) Drosophila santomea, fruit fly () Drosophila sechellia, fruit fly (2007) Drosophila simulans, fruit fly (2007) Drosophila takahashi, fruit fly (2011) Drosophila virilis, fruit fly (2007) Drosophila willistoni, fruit fly (2007) Drosophila yakuba, fruit fly (2007) Family Phoridae Megaselia abdita, scuttle fly (transcriptome 2013) Family Psychodidae (drain flies) Clogmia albipunctata, moth midge (transcriptome 2013) Family Sarcophagidae (flesh flies) Sarcophaga Bullata, Flesh fly (2019) Family Syrphidae (hoverflies) Episyrphus balteatus, hoverfly (transcriptome 2011) Order Hemiptera Acyrthosiphon pisum, aphid (pea aphid) (2010) Ericerus pela, Chinese wax scale insect (2019) Laodelphax striatellus, small brown planthopper (2017) Lycorma delicatula, spotted lanternfly (2019) Rhodnius prolixus, kissing-bug (2015) Rhopalosiphum maidis, Corn leaf aphid (2019) Sitobion miscanthi, Indian grain aphid (2019) Triatoma rubrofasciata, assassin bug (2019) Order Hymenoptera Acromyrmex echinatior colony Ae372, ant (Panamanian leafcutter) (2011) Apis mellifera, bee (honey bee), (model for eusocial behavior) (2006) Atta cephalotes, ant (leaf-cutter ant) (2011) Camponotus floridanus, ant (2010) Cerapachys biroi, ant (clonal raider ant)(2014) Euglossa dilemma, Green orchid bee (2017) Harpegnathos saltator, ant (2010) Lasius niger, ant (black garden ant)(2017) Linepithema humile, ant (Argentine ant) (2011) Nasonia giraulti, wasp (parasitoid wasp) (2010) Nasonia longicornis, wasp (parasitoid wasp) (2010) Nasonia vitripennis, wasp (parasitoid wasp; model organism) (2010) Netelia fuscicornis, wasp (parasitoid wasp) (2024) Nomia Melanderi, Alkali bee (2019) Pogonomyrmex barbatus, ant (red harvester ant) (2011) Solenopsis invicta, ant (fire ant) (2011) Order Lepidoptera Abrostola tripartita Hufnagel, Spectacle (2021) Achalarus lyciades, Hoary Edge Skipper (2017) Ahamus jianchuanensis, Jianchuan ghost moth (2024) Antharaea yamamai, Japanese oak silk moth (2019) Arctia plantaginis, Wood tiger moth (2020) Bicyclus anynana, squinting bush brown (2017) Bombyx mori Strain:p50T, moth (domestic silk worm) (2004) Calycopis cecrops, Red-Banded Groundstreak (2016) Calycopis isobeon, Dusky-Blue Groundstreak (2016) Coenonympha arcania, Pearly Heath (2024) Cydia pomonella, codling moth (2019) Danaus plexippus, monarch butterfly) (2011) Erebia cassioides, Common Brassy Ringlet (2025) Heliconius melpomene, butterfly (2012) Keiferia lycopersicella, Tomato pinworm (2024) Melitaea cinxia, Glanville fritillary butterfly (2014) Megathymus ursus violae, bear giant skipper butterfly (2018) Morpho helenor, Common blue morpho (2023) Morpho achilles, Blue-banded morpho (2023) Morpho deidamia (2023) Papilio bianor, Chinese peacock butterfly (2019) Phthorimaea absoluta, Tomato leafminer (2024) Pieris rapae, small cabbage white butterfly (2016) Plodia interpunctella, Indianmeal moth (2022) Plutella xylostella, moth (diamondback moth) (2013) Scrobipalpa atriplicella, Goosefoot groundling moth (2024) Spodoptera frugiperda, Fall armyworm (2017) Thitarodes armoricanus, Himalaya ghost moth (2024) Thitarodes xiaojinensis, Xiaojin ghost moth (2024) Troides aeacus, Golden birdwing (2024) Eudocima phalonia, fruit-piercing moth (2017) Order Orthoptera Locusta migratoria, migratory locust (2014) Schistocerca gregaria, desert locust (2020) Gryllus bimaculatus, two-spotted cricket (2021) Order Phthiraptera Pediculus humanus, louse (sucking louse; parasite) (2010) Menopon gallinae, Poutlry shaft louse (2024) Psocoptera Liposcelis brunnea, booklouse (2022) Order Raphidioptera Venustoraphidia nigricollis, black-necked snakefly (2023) Order Trichoptera Eubasilissa regina, purple caddisfly (2022,) Stenopsyche tienmushanensisi, Caddisfly (2018) Order Mantodea Tenodera sinensis, chinese praying mantis (2023)
== History == Before automated cell counters were introduced, cell counts were performed manually; white and red blood cells, and platelets were counted using microscopes. The first person to publish microscopic observations of blood cells was Antonie van Leeuwenhoek, who reported on the appearance of red cells in a 1674 letter to the Proceedings of the Royal Society of London; Jan Swammerdam had described red blood cells some years earlier, but had not published his findings at the time. Throughout the 18th and 19th centuries, improvements in microscope technology such as achromatic lenses allowed white blood cells and platelets to be counted in unstained samples. In the 1870s, Paul Ehrlich developed a staining technique that could differentiate between the five white blood cell types. Ehrlich's stain used a combination of an acidic and basic dye to stain white and red blood cells simultaneously. Dmitri Leonidovich Romanowsky improved on this technique in the 1890s by using a mixture of eosin and aged methylene blue, which produced a wide range of hues that was not present when either of the stains was used alone. This was termed the Romanowsky effect and became the basis for Romanowsky staining, the technique that is still used to stain blood smears for manual differentials. By the early years of the 20th century, the white blood cell differential had become a common practice in the United States, but difficulties in interpreting the results cast doubt on the test's utility.
== History == BioDuro was founded in 1996 in the United States as a drug discovery services company. In 2009, it was acquired by Pharmaceutical Product Development (PPD), a leading global contract research organization. In 2020, Advent International merged BioDuro with the China-based CRO Sundia to form BioDuro-Sundia, creating a combined CRDMO serving biotech and pharma clients globally. In 2021, the company expanded its U.S. operations in Irvine to support clinical and commercial drug product manufacturing. In 2025, BioDuro announced new investments in China, including a Bengbu process development and scale-up site and an OEB-5 high-potency laboratory for ADC payloads and HPAPIs.
Sources: en.wikipedia.org
The Royal Navy enlisted 184,899 sailors during the Seven Years' War; 133,708 were "lost", either dying of sickness, being discharged as physically unfit or deserting, with scurvy as the leading cause of death. Although sailors and naval surgeons were increasingly convinced that citrus fruits could cure scurvy throughout this period, the classically trained physicians who determined medical policy dismissed this evidence as merely anecdotal, as it did not conform to their theories of disease. Literature championing the cause of citrus juice had no practical impact. The medical theory was based on the assumption that scurvy was a disease of internal putrefaction brought on by faulty digestion caused by the hardships of life at sea and the naval diet. Although successive theorists gave this basic idea different emphases, the remedies they advocated (and which the navy accepted) amounted to little more than the consumption of 'fizzy drinks' to activate the digestive system, the most extreme of which was the regular consumption of 'elixir of vitriol' – sulphuric acid taken with spirits and barley water, and laced with spices. In 1764, a new and similarly inaccurate theory on scurvy appeared. Advocated by Dr David MacBride and Sir John Pringle, Surgeon General of the Army and later President of the Royal Society, this idea was that scurvy was the result of a lack of 'fixed air' in the tissues which could be prevented by drinking infusions of malt and wort whose fermentation within the body would stimulate digestion and restore the missing gases.
==== Structural problems ==== Structurally, changes within the musculature in the intestine, such as increased elastin, can lead to increased frequency of herniation. Laxity of the phreno-esophageal and gastro-hepatic ligaments can lead to hiatal hernia, which in turn can lead to commonly reported symptoms such as acid reflux, abdominal pain, early satiety, and bloating. Internal organ prolapses and intestinal intussusceptions occur with greater frequency in patients with weakened connective tissues.
== Overview == Source Filmmaker is a tool for animating, editing and rendering 3D animated videos using assets from most games which use the Source engine, such as sounds, models, and, backdrops. SFM also allows for the creation of still images, art, and posters. SFM contains three different user interfaces and a "work camera" for previewing an active scene. The three interfaces are used for creating clips, controlling animation, and making fine-tuned adjustments, which include:
Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was studied by Pfizer as a potential treatment of metabolic disorders such as type 2 diabetes mellitus. Its development was terminated in 1999.
== Impact on protein function == Missense mutation refers to a change in one amino acid in a protein arising from a point mutation in a single nucleotide. Amino acids are the building blocks of proteins. Missense mutations are a type of nonsynonymous substitution in a DNA sequence. Two other types of nonsynonymous substitutions are nonsense mutations, in which a codon is changed to a premature stop codon that results in the resulting protein being cut short, and nonstop mutations, in which a stop codon deletion results in a longer but nonfunctional protein. The latter two types are not considered to be missense mutations.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.